Originally published in the Journal of Applied Nutrition, 1973

Appendix, References, Bibliography

Appendix
Since presenting this paper, we have observed that improvement in all categories is enhanced when the intravenous injection contains 800 mg. to 1000 mg. thiamin hydrochloride, 200 mg. pyridoxine, 400 mg. niacinamide, 100 mg. nicotinic acid. The thiamin hydrochloride solution must be clear. The amount of niacin employed must be calculated from the “flush factor” of a given patient. The injection is made with a 20cc or 30cc syringe, using a 23G x 3/4 inch or 22G x 1 inch needle. Intravenous medication can be given daily; it should be administered at least twice weekly. Due to sensitivity possibilities, we always have the patient take the intramuscular injections for three weeks before starting intravenous therapy.

Bibliography – Papers
1. Stern, E.L.: The Intraspinal Injection of Vitamin B1 for the Relief of Intractable Pain, and for Inflammatory and Degenerative Diseases of the Central Nervous System. Am. J. Surg. 34:495, 1938.
2. Rosenberg, L.E.: Vitamin Deficiency Diseases and the Vitamin Dependent Diseases with Reference to B and D. Natl. Health Fed’n. Bulletin Vol. XVIII, No. 10, November 1972.
3. Moore, M.T.: Treatment of Multiple Sclerosis with Nicotinic Acid and Vitamin B1. Archives Int. Med. Vol. 65, pp. 18, Jan. 1940.
4. Bijou, S.W.; Baer, I.M.: Child Development II Universal Stage of Infancy. Appleton-Century-Crofts, 1965.
5. Kempe, C.H.: Key to the Secret of MS. Medical World News, July 7, 1972.
6. Alter, M. et al.: Dissertation on Environmental and Sleeping Virus Theory. Medical Tribune.
7. Schandl, D.K.: Dissertation on Environmental and Pyridoxine Cause of MS. The Charlotte Observer, Charlotte, NC. April 23, 1973.
8. Dahl, Doris; Bignami, Amico: Report of Substance Preventing Renewal Myelin. Reidsville Review, April 23, 1973.
9. Brickner, R.M.: A Critique of Therapy in Multiple Sclerosis. Bulletin Neur. Inst., New York, Vol. 4:665, April 1936.
10. Zimmerman, H.H.; Burack, F: Lesions of the Nervous System Resulting from a Deficiency of the Vitamin B Complex. Arch. Pathology, Vol. 13:207, February 1932.
11. Spies, T.D.; Cooper, C.; Blankenhorn, M.A.: The Use of Nicotinic Acid in the Treatment of Pellagra. JAMA, Vol. 110:622, February, 1936.
12. Spies, T.D.; Aring, C.D.: The Effect of Vitamin B1 on the Peripheral Neuritis of Pellagra. JAMA, Vol. 110:1081, April 1938.
13. Klenner, F.R.: Fatigue-Normal and Pathological with Special Consideration of Myasthenia Gravis and Multiple Sclerosis. Southern Medicine and Surgery, Vol. III, No. 9; September 1949.
14. Flexner, S.; Lewis, P.A.: Experimental Poliomyelitis in Monkeys. Journal Experimental Medicine, Vol. 12:227, 1910.

Bibliography – Textbooks
a. Alpers, B.J.: Clinical Neurology, 2nd Ed., F.A. Davis Co., 1950.
b. Bodansky, M.: Intro. to Physiological Chemistry, 2nd Ed. John Wiley & Sons, Inc., 1930.
c. Cameron, A.T.; Gilmour, C.R.: The Biochemistry of Medicine. William Wood & Co., 1933.
d. Evans, A.L.; Hartridge, E.: Starling’s Principles of Human Physiology 5th Ed., J&A Churchill, London, 1930.
e. Fieser, L.F.; Fieser, Mary: Organic Chemistry. 3rd Ed., D.C. Heath and Company, 1956.
f. Harrow, B.: Casimir Funk: Pioneer in Vitamins & Hormones. Dodd, Mead & Co., New York, 1955.
g. Hawk, P.B.; Oser, B.L.; Summerson, W.E.: Practical Physiological Chemistry. 13th Ed., McGraw-Hill Book Co. Inc., 1954.
h. Lichtman, S.S.: Diseases of the Liver, Gallbladder and Bile Ducts, Vol. I, Lea & Febiger, Philadelphia, 1953.
I. Lowenberg, S.A.: Medical and Physical Diagnosis. 7th Ed. F.A. Davis Co., 1948.
j. Martin, H.N.; Martin, E.G.: The Human Body. 11th Ed. Revised. Henry Holt and Co., 1932.
k. Srb, A.M.; Owen, R.A.; Edgar, R.S.: General Genetics, 2nd Ed., W.H. Freeman and Co., 1965.
l. The Merck Manual, 12th Ed. Merck & Co., Inc., Rahway, NJ 1972.
m. The Vitamins: A Symposium, 1939, AMA.
n. Vander, A.J.: Sherman, J.H.; Luciano, D.S.: Human Physiology McGraw-Hill Inc., 1970.
o. Wells, H.C.: Chemical Pathology, 5th Ed. Revised. W.B. Saunders Co., 1925.